Search

Displaying results 5631 - 5640 of 10000 in total
  1. Drug

    Black walnut

    go.drugbank.com/drugs/DB10919
    Approved

    Black walnut allergenic extract is used in allergenic testing.

  2. Drug

    Cephalosporium roseum

    go.drugbank.com/drugs/DB10932
    Approved

    Cephalosporium roseum allergenic extract is used in allergenic testing.

  3. Drug

    Absidia capillata

    go.drugbank.com/drugs/DB10972
    Approved

    Absidia capillata allergenic extract is used in allergenic testing.

  4. Drug

    Trichosporon cutaneum

    go.drugbank.com/drugs/DB10974
    Approved

    Trichosporon cutaneum allergenic extract is used in allergenic testing.

  5. Drug

    Tasquinimod

    go.drugbank.com/drugs/DB05861
    Investigational

    The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts

  6. Drug

    Pelitinib

    go.drugbank.com/drugs/DB05524
    Investigational

    Pelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.

    Synonyms: (2E)-N-(4-((3-chloro-4-fluorophenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamide
  7. Drug

    Saredutant

    go.drugbank.com/drugs/DB06660
    Investigational

    Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.

  8. Drug

    Cinchophen

    go.drugbank.com/drugs/DB13551
    Experimental

    Categories: Preparations With No Effect on Uric Acid Metabolism
  9. Drug

    Ethacizine

    go.drugbank.com/drugs/DB13645
    Experimental

    Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class Ic
  10. Drug

    Apronalide

    go.drugbank.com/drugs/DB13221
    Approved

    Apronalide is approved in Japan. Apronalide has been withdrawn from the market in many other countries due to patient development of thrombocytopenic purpura [A174814].